XML 28 R15.htm IDEA: XBRL DOCUMENT v3.26.3
Revenues
 9 Months Ended
Sep. 30, 2026
Revenue from Contract with Customer [Abstract]  
Revenues Revenues
Product Revenue, Net
The Company’s product revenue is derived from the sales of its commercial products in Greater China. The table below presents the Company’s gross and net product revenue ($ in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Product revenue - gross115,784 127,103 331,713 355,965 
Less: Rebates and sales returns(8,136)(11,742)(22,758)(25,870)
Product revenue - net107,648 115,361 308,955 330,095 
Sales rebates are offered to distributors in mainland China, and the amounts are recorded as a reduction of product revenue. Estimated rebates are determined based on contracted rates, sales volumes, and level of distributor inventories.
The following table presents the Company’s net revenue by commercial program ($ in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
ZEJULA32,284 42,432 94,330 133,002 
VYVGART / VYVGART Hytrulo24,071 27,727 65,488 72,329 
NUZYRA21,089 15,430 54,448 44,840 
OPTUNE7,821 12,657 32,093 36,375 
QINLOCK8,829 8,901 27,404 25,946 
XACDURO8,421 6,445 24,950 12,184 
AUGTYRO2,822 1,677 6,827 4,702 
KarXT2,015 — 2,567 — 
Other (i)296 92 848 717 
Product revenue - net107,648 115,361 308,955 330,095 
(i)Other includes product candidates sold in patient programs prior to commercialization.
Collaboration Revenue
Collaboration revenue was $0.6 million and $5.2 million in the three and nine months ended September 30, 2026, respectively, and $0.7 million and $2.5 million in the three and nine months ended September 30, 2025, respectively, and mainly related to a regional license and collaboration arrangement and promotional activities in mainland China.